The combination of IGF1 and FGF2 and the induction of excessive ocular growth and extreme myopia.
Different growth factors have been shown to influence the development of form-deprivation myopia and lens-induced ametropias. However, growth factors have relatively little effect on the growth of eyes with unrestricted vision. We investigate whether the combination of insulin-like growth factor 1 (IGF1) and fibroblast growth factor 2 (FGF2) influence ocular growth in eyes with unrestricted vision. Different doses of IGF1 and FGF2 were injected into the vitreous chamber of postnatal chicks. Measurements of ocular dimensions and intraocular pressure (IOP) were made during and at the completion of different treatment paradigms. Histological and immunocytochemical analyses were performed to assess cell death, cellular proliferation and integrity of ocular tissues. Treated eyes had significant increases in equatorial diameter and vitreous chamber depth. With significant variability between individuals, IGF1/FGF2-treatment caused hypertrophy of lens and ciliary epithelia, lens thickness was increased, and anterior chamber depth was decreased. Treated eyes developed myopia, in excess of 15 diopters of refractive error. Shortly after treatment, eyes had increased intraocular pressure (IOP), which was increased in a dose-dependent manner. Seven days after treatment with IGF1 and FGF2 changes to anterior chamber depth, lens thickness and elevated IOP were reduced, whereas increases in the vitreous chamber were persistent. Some damage to ganglion cells was detected in peripheral regions of the retina at 7 days after treatment. We conclude that the extreme myopia in IGF1/FGF2-treated eyes results from increased vitreous chamber depth, decreased anterior chamber depth, and changes in the lens. We propose that factor-induced ocular enlargement and myopia result from changes to the sclera, lens and anterior chamber depth.
College of Optometry, The Ohio State University, Columbus, OH 43210, USA.
Eric R
ER
Ritchey
Christopher P
CP
Zelinka
Junhua
J
Tang
Jun
J
Liu
Andy J
AJ
Fischer
D000818:Animals; D000831:Animals, Newborn; D000867:Anterior Chamber / Q000187:drug effects / Q000473:pathology; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002645:Chickens; D002924:Ciliary Body / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005123:Eye / Q000187:drug effects* / Q000254:growth & development; D016222:Fibroblast Growth Factor 2 / Q000633:toxicity*; D006984:Hypertrophy; D020287:In Situ Nick-End Labeling; D007334:Insulin-Like Growth Factor I / Q000633:toxicity*; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D007908:Lens, Crystalline / Q000187:drug effects / Q000473:pathology; D047728:Myopia, Degenerative / Q000139:chemically induced* / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D017526:Receptor, IGF Type 1 / Q000235:genetics; D011972:Receptor, Insulin / Q000235:genetics; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics; D012160:Retina / Q000187:drug effects / Q000473:pathology; D042262:Retinoscopy; D020133:Reverse Transcriptase Polymerase Chain Reaction
D004338:Drug Combinations; D012333:RNA, Messenger; D017468:Receptors, Fibroblast Growth Factor; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin